EMA Authorised: Evista (raloxifene hydrochloride) — Substipharm

View source ↗

Summary

EMA has authorised Evista (raloxifene hydrochloride) for postmenopausal osteoporosis; the marketing authorisation holder is Substipharm.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Evista (raloxifene)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Substipharm. Decision date: 01/04/2025